GSK announces Dr Anne Beal to join the Board as Non-Executive Director
For media and investors only
Issued: London, UK
GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that Dr Anne Beal will join the Board of the Company as a Non-Executive Director with effect from 6 May 2021.
On joining the Board, Dr Beal will become a member of the Corporate Responsibility Committee (the ‘Committee’) which provides important oversight of the Company’s Trust agenda including policies towards access to medicines, global health, inclusion and diversity and environmental sustainability. Dr Beal will succeed Lynn Elsenhans as Chair of the Committee after the 2022 Annual General Meeting. Ms Elsenhans has agreed to remain on the Board for a further year to facilitate an orderly transition to Dr Beal’s leadership of the Committee.
Dr Beal will bring to GSK extensive healthcare experience as a physician and entrepreneur combined with a passion for patient advocacy. She is a recognised health policy expert in the development of global and national programmes for improving healthcare access for all patient groups and in ensuring the voice of patients is reflected in research programmes.
Commenting on the changes, Sir Jonathan Symonds, Chairman of GSK said: “I am delighted to welcome Anne to GSK. Acting responsibly is an integral part of how successful modern businesses deliver for a wide range of stakeholders including investors. That’s why the work of the Corporate Responsibility Committee is critical to the success of GSK. Anne’s expertise and experience will be a valuable addition to GSK and to the leadership of the Committee. I would like to thank Lynn for her service to the Company over the last nine years and to agreeing to stay on to ensure a smooth transition to Anne.”
Dr Beal is founder and CEO of AbsoluteJOI Skincare and a member of the Board of AcademyHealth. Prior to her current roles, Dr Beal spent six years at Harvard Medical School and Massachusetts General Hospital, where she was an instructor in paediatrics and has also held leadership roles at the Commonwealth Fund and the Aetna Foundation. In addition, Dr Beal was previously Deputy Executive Director and Chief Engagement Officer for The Patient-Centered Outcomes Research Institute in the U.S. and Chief Patient Officer and Global Head of Patient Solutions at Sanofi.
She holds a B.A. from Brown University, an M.D. from Cornell University Medical College, and an M.P.H. from Columbia University.
Notes
- The appointment of Dr Anne Beal was made by the Board on the recommendation of the Nominations & Corporate Governance Committee.
- The Board has determined that Dr Beal will be an independent Non-Executive Director on appointment in accordance with the UK Corporate Governance Code.
- Dr Beal will receive the standard basic fee for a Non-Executive Director of £95,000 per annum. She will receive a further payment of £40,000 per annum when she succeeds Ms Elsenhans as Chair of the Corporate Responsibility Committee.
Dr Beal will be required to invest at least 25% of her fees in GSK shares that should be held until her retirement from the Board. - Membership of other Committees will be determined in due course.
- Dr Beal does not have a service contract. She has a letter of appointment which may be viewed by contacting the Company Secretary at the Company’s registered office.
- There are no additional details to disclose in respect of Dr Beal’s appointment under Listing Rule 9.6.13R.
- From 6 May 2021 the Board of GSK will comprise:
|
Sir Jonathan Symonds Emma Walmsley Iain Mackay Dr Hal Barron Vindi Banga Charles Bancroft Dr Anne Beal Dr Vivienne Cox Lynn Elsenhans Dr Jesse Goodman Dr Laurie Glimcher Urs Rohner |
Non-Executive Chairman Chief Executive Officer Chief Financial Officer Chief Scientific Officer and President, R&D Senior Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director |
As previously announced, Charles Bancroft has succeeded Judy Lewent as Chair of the Audit & Risk Committee following approval of GSK's 2020 Annual Report. Judy will not stand for re-election to the Board at GSK’s Annual General Meeting on 5 May 2021.
Lynn Elsenhans will stand for re-election at the AGM and remain on the Board for a further year to facilitate a smooth handover to Dr Beal.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2020 and any impacts of the COVID-19 pandemic.
